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A B S T R A C T
Sublingual buprenorphine is used in opioid maintenance treatment but buprenorphine is also widely
abused and causes fatal poisonings. The aim of this study was to investigate buprenorphine-positive
fatalities in order to gain novel information on the magnitude and nature of buprenorphine abuse.
All post-mortem toxicology cases positive for urinary buprenorphine, including fatal poisonings
caused by buprenorphine and fatalities in which the cause of death was unrelated to buprenorphine, in
the ﬁve year period of 2010–2014 in Finland were characterized according to urine buprenorphine and
naloxone concentrations (n = 775). Urine concentrations were used to assess which buprenorphine
preparation had been used; mono-buprenorphine or a buprenorphine-naloxone combination, and
whether they had been administered parenterally.
In at least 28.8% of the buprenorphine-positive cases the drug had been administered parenterally. The
majority of the parenteral users (68.6%) had taken mono-buprenorphine. Fatal poisoning was
signiﬁcantly more common among the identiﬁed parenteral users (65.5%) than among other users of
buprenorphine products (45.3%). The proportion of buprenorphine-related poisoning was similar in
identiﬁed parenteral users of mono-buprenorphine (68.6%) and buprenorphine-naloxone (64.1%). In
nearly all of the fatal poisoningss the deceased had used other drugs and/or alcohol along with
buprenorphine (98.7%). The median age of the deceased increased signiﬁcantly over the study period,
from 32 to 38 years.
Our results show that there is ongoing parenteral abuse of both mono-buprenorphine and
buprenorphine-naloxone combination. Parenteral users of buprenorphine put themselves into a great
risk of fatal poisoning or other accidental injury death which is further exacerbated by the frequent poly-
drug use.
© 2018 Elsevier B.V. All rights reserved.
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Opioids cause more fatal drug poisonings in the European
Nordic countries than any other pharmacological drug class, and, in
Finland buprenorphine is the most commonly abused opioid [1].
Buprenorphine is a semi-synthetic partial agonist at the m-opioid
receptor with antagonist activity at the k-opioid receptor.
Sublingual buprenorphine (Subutex1, BPN) has been used in the
treatment of opioid dependence in Finland since 2000 and has
been shown to be safe in opioid maintenance treatment (OMT) [2].
Buprenorphine has a special history in Finland: two general
practitioners in Helsinki introduced the use of buprenorphine for
the treatment of opioid addicts in the 1990s [3]. However, the
Finnish authorities considered their methods and integrity to be
questionable and later one of the physicians was found guilty of* Corresponding author at: Forensic Toxicology Unit, National Institute for Health
and Welfare, P.O.Box 30, 00271 Helsinki, Finland.
E-mail address: pirkko.kriikku@thl.ﬁ (P. Kriikku).
https://doi.org/10.1016/j.forsciint.2018.08.010
0379-0738/© 2018 Elsevier B.V. All rights reserved.smuggling and selling buprenorphine tablets to his patients. This
early introduction of buprenorphine likely inﬂuenced the evolu-
tion of the Finnish recreational drug scene so that currently there is
frequent parenteral abuse (injecting or snorting the drug) of
buprenorphine while parenteral use of heroin is less common [1].
BPN was ﬁrst started in OMT in Finland in 1997 [4]. During the
2000s, the use of OMT increased and was implemented by health
centres [3]. A combination of buprenorphine and naloxone for
sublingual administration (Suboxone1, BNX) became available at
the end of 2003. Several treatment centres switched their patients
rapidly from BPN to BNX because the combination sublingual
product appears to be less likely to be solubilized and abused
parenterally, although this does still occur [5]. With the exception
of some programs that still treat pregnant women with BPN, since
2009, BNX has been the sole buprenorphine-containing product
used to treat OMT patients in Finland. In 2015, 63% of the Finnish
OMT patients were taking buprenorphine or buprenorphine
containing combinations and 37% were taking methadone [6].
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medically supervised use compared to, e.g., methadone [7], results
from several French case series suggested that intravenous abuse
of buprenorphine, when associated with other psychotropic drugs,
is a major risk factor for fatal poisoning [8–10]. A later population-
based Finnish study conﬁrmed that benzodiazepines and alcohol
are associated with cases of fatal buprenorphine poisoning [11]. In
addition, animal studies have shown that buprenorphine can cause
respiratory depression, especially when administered together
with alcohol [12] or other central nervous system depressants such
as benzodiazepines [13,14], but the interaction is complex and not
yet thoroughly understood [12,15–17]. In any case, fatal poisoning
by buprenorphine alone without other central nervous system
depressants seems to be uncommon [8–13]. In Finland, opioid
users generally take multiple drugs of abuse from different
pharmacological classes and the majority of fatal poisonings of
opioid dependent individuals are poly-drug poisonings [1].
Surveys have indicated that intravenous injection is the most
common route of administration for individuals abusing bupre-
norphine [18–20]. Since the introduction of BNX it has become
evident that both sublingual formulations, BPN and BNX,
are abused intravenously, although the latter to a lesser extent
[21–23]. In addition, BPN and BNX are also subject to considerable
diversion and trafﬁcking [24–26]. Until recently, it has not been
possible to differentiate between BPN and BNX abuse by laboratory
analysis. Our earlier study, based on post-mortem toxicology
investigation in Finland, was the ﬁrst laboratory-based study to
assess whether these drugs had been administered parenterally,
and the study demonstrated the toxicity associated with paren-
teral abuse of BPN and BNX [27].
In this study, our objective was to investigate BPN and BNX
abuse and fatal poisonings in a larger study population and look for
trends over time, using our previously published methodology to
determine which buprenorphine product had been abused [27].
2. Material and methods
All deaths in the medicolegal investigations involving bupre-
norphine in the ﬁve-year period between 2010 and 2014 were
examined in this study.
In Finland, all sudden and unexpected deaths are required by
law to undergo a medicolegal investigation, initiated by the police
and conducted by a forensic pathologist. As a result, in nearly 20%
of all deaths a medicolegal investigation is performed with an even
higher percentage in younger individuals.
In most medicolegal cases during the study period, the forensic
pathologist had requested a post-mortem toxicological examina-
tion. This included the screening of post-mortem urine by ultra-
high performance liquid chromatography coupled with high-
resolution time-of-ﬂight mass spectrometry (LC–TOFMS) [28,29],
screening and quantiﬁcation of post-mortem blood by gas
chromatographic (GC) methods [30], and additional conﬁrmation
analyses of drugs of abuse by LC–MS/MS and GC–MS methods. The
toxicological screening covered more than 700 drugs and poisons,
including opioids, amphetamines, cannabinoids and benzodiaze-
pines.Table 1
Median urine concentrations (mg/L), 95% conﬁdence intervals (95% CI), and concentrat
Parenteral BNX Parenteral 
N Median (95% CI) Range N M
Buprenorphine 70 180 140–220 21–1300 153 11
Norbuprenorphine 69 64 29–100 1.2–1000 149 51
Naloxone 70 220 170–260 100–2600 0 Buprenorphine, its major active metabolite norbuprenorphine,
and naloxone were screened by LC–TOFMS in post-mortem urine
after treatment with β-glucuronidase to release free drug from
glucuronides [28,29]. Quantiﬁcation was performed by an LC–MS/
MS method described elsewhere [31]. The lower limit of
quantiﬁcation (LLOQ) in urine for each of the studied substance
was 0.10 mg/L. Ethanol was analysed in post-mortem blood by
headspace gas chromatography and a laboratory cut-off of 0.2 g/kg
was applied.
In addition to the analytical results, demographic character-
istics and information from the death certiﬁcate issued by forensic
pathologist were collected. Mortality rates were calculated as the
number of deaths per 100,000 inhabitants in the 15–64-years-old
age group.
2.1. Data selection and subgroups
Medicolegal cases, in which the urine sample was positive for
buprenorphine, were divided into three groups according to the
urine buprenorphine and naloxone concentrations, using the
criteria previously developed by analysing a series of urine samples
from living individuals in an OMT program [31]: “Parenteral BNX”,
“Parenteral BPN” and “Other BNX and BPN”. These criteria enable
post-mortem cases to be categorized according to the route of
administration and the preparation used [27].
The grouping criteria in our study have been deﬁned so that the
parenteral user groups should not include many individuals that
have taken the drug sublingually. However, although the group
“other BNX and BPN” contains mostly sublingual users in the study,
it is likely to also contain cases of parenteral users.
The cause and manner of death were deﬁned by the forensic
pathologist based on autopsy ﬁndings, background information
and laboratory results including forensic toxicology, biochemistry
and DNA analysis, when requested. In this study, the cases were
categorized into the following manners of death: accident, illness,
suicide and other (incl. homicide, occupational disease, undeter-
mined intent and trafﬁc death).
2.2. Statistical evaluation
All statistical analyses were carried out using IBM SPSS software
(version 22.0). As the frequency distributions of the urine
concentrations and the age of the deceased were skewed, medians
were used to characterize the data.
2.3. Ethical issues
The study was conducted in accordance with all applicable local
and international laws and regulations. For this type of study,
formal consent is not required.
3. Results
In the ﬁve year period between 2010 and 2014, post-mortem
toxicology was applied to 33,420 cases. The total number of cases
that met the inclusion criteria of this study (urine sample positiveion ranges of buprenorphine, norbuprenorphine and naloxone in each user group.
BPN Other BNX or BPN
edian (95% CI) Range N Median (95% CI) Range
0 96–120 50–1500 552 15 12–17 1–680
 31–71 1.2–520 494 12 10–14 1–700
171 20 15–25 1–98
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that time period. Of the urine samples in the studied 775 cases, 712
(91.9%) contained norbuprenorphine and 241 (31.1%) contained
naloxone. The mean and median concentrations of buprenorphine,
norbuprenorphine and naloxone in different user groups are given
in Table 1.
3.1. User groups
Of the 775 cases selected for the study, in 223 (28.8%) the
measured urine concentrations indicated recent parenteral ad-
ministration of buprenorphine. In 70 of these (9.0% of all
buprenorphine positive cases), naloxone was detected together
with buprenorphine indicating recent parenteral administration of
BNX. In 153 (19.7% of all buprenorphine positive cases) of the
parenteral buprenorphine cases no naloxone was detected
indicating recent parenteral administration of BPN or another
mono-buprenorphine preparation. In the remaining 552 (71.2%)
cases the measured urine concentrations were below the threshold
that would identify them as parenteral users, although some could
be parenteral users whose urine levels had failed to achieve or had
fallen below the thresholds.
No signiﬁcant changes in the total number of buprenorphine-
positive cases in the ﬁve consecutive years were observed. Also, the
proportion of cases in each group remained relatively stable over
the study period (Table 2).
The median (range) age of the deceased in the study population
was 33 (18–98) years with 89.9% being aged 15–64. Further
breakdown of the yearly numbers is given in Table 2.
The median age of the deceased was signiﬁcantly lower in the
parenteral BNX and BPN groups when compared to the group
“other BNX or BPN” (P = 0.001 and P < 0.001, respectively).
However, no signiﬁcant difference was detected between the
two groups of parenteral users. The age of the deceased increased
signiﬁcantly over the study period (p < 0.001) (Fig. 1).
Of the total 775 buprenorphine-positive cases, 83% were males,
and the proportion of males was over 80% in each of the three user
groups. The gender distribution in different age groups and in the
three user groups is illustrated in Fig. 2. Differences were observed
in the proportion of males in different age groups, especially
among the oldest individuals: in the age group 60 years and above,
the precentage of males was 54.5% (p < 0.001).
3.2. Fatal poisonings and concomitant use of other drugs
Of the 775 studied cases, 396 (51.1%) were fatal poisonings in
which buprenorphine was implicated as the cause of death by theTable 2
Number of deceased, and median age and gender in each user group during
2010–2014.
2010 2011 2012 2013 2014 TOTAL
Parenteral BNX
N 23 13 13 11 10 70
Median age (y) 28 32 28 36 35 31
Males (%) 83 92 92 100 80 89
Parenteral BPN
N 35 31 23 28 36 153
Median age (y) 29 30 30 29 37 31
Males (%) 77 87 82 86 92 85
Other BNX or BPN
N 101 108 100 123 120 552
Median age (y) 33 33 36 37 41 36
Males (%) 84 81 83 80 82 82
TOTAL
N 159 152 136 162 166 775
Median age (y) 32 31 33 35 38 33
Males (%) 82 83 84 82 84 83forensic pathologist. Buprenorphine was considered to be the
primary ﬁnding in 256 of the fatal poisonings (33.0%) (Table 3.).
The proportion of buprenorphine poisonings was signiﬁcantly
higher in the groups “parenteral BNX” (68.6%) and “parenteral
BPN” (64.1%) than in the group “other BNX or BPN” (45.3%)
(p = 0.001 and p < 0.001, respectively).
The yearly number of fatal buprenorphine poisonings de-
creased signiﬁcantly during the study period (p < 0.05). Accord-
ingly, the mortality rate calculated per 100,000 Finnish inhabitants
between 15 and 64 years of age decreased from 2.7 to 1.9. Of the
studied user groups, the decrease in the number of fatal poisonings
was signiﬁcant in all except in the group “parenteral BPN”. A
further breakdown of the poisoning numbers is given in Table 4.
There were ﬁve fatal poisonings in which no other psychoactive
substances, besides buprenorphine, were present in pharmaco-
logically relevant concentrations. A typical example of these ﬁve
mono-intoxications was a case in which a 28-year old male was
found dead in his apartment lying next to a syringe and, in addition
to buprenorphine, only cannabis (at a below pharmacologically
relevant level) was detected in post-mortem toxicology.
The blood alcohol concentration (BAC) was above the laborato-
ry cut-off of 0.2 g/kg in 281 cases (37.2%) and above 0.5 g/kg in 235
cases (30.3%), the highest BAC being 3.4 g/kg. The mean BAC was
1.33 g/kg for all blood alcohol-positive cases, 1.10 g/kg for blood
alcohol-positive “parenteral BNX” group and 1.20 g/kg for blood
alcohol-positive “parenteral BPN” group. The percentage of cases
with a BAC above the laboratory cut-off of 0.2 g/kg was slightly
lower in the groups of parenteral users (BNX 30.0% and BPN 33.3%)
compared to the group “Other BNX and BPN” but the difference
was not statistically signiﬁcant. Among those who died of fatal
buprenorphine poisoning, 45.2% had a BAC over the cut-off of 0.2 g/
kg with a mean BAC of 1.37 g/kg.
3.3. Manner of death
In the majority of the studied buprenorphine-positive cases the
manner of death determined by the forensic pathologist was
accident (60.0%). The proportion of accidental deaths was higher
among parenteral users: “Parenteral BNX” (70.0%) and “Parenteral
BPN” (62.1%) compared to the group “Other BNX and BPN” (57.8%)
but the difference was not statistically signiﬁcant. Other major
manners of death in the study population were illness (21.5%) and
suicide (11.2%). Further breakdown of the numbers in different
user groups is illustrated in Fig. 3.
4. Discussion
Based on the laboratory analysis, 223 (28.8%) of the 775
deceased included in the study could be identiﬁed as parenteral
users of buprenorphine preparations. This is in line with the results
of our previous study in which the proportion was 31.1% [27]. This
number must be considered a minimum since the urine concen-
trations of some parenteral users may not have reached, or may
have fallen below, the threshold levels at the time of death. Such
cases could not be distinguished from sublingual users and would
not be included in the parenteral groups.
Even though the quantity of BPN used for approved medical
purposes in Finland is very much less than that of BNX, most of the
identiﬁed parenteral users had been using BPN (153) rather than
BNX (70). Some mono-buprenorphine preparations are available in
Finland for the treatment of severe pain, including for example,
Norspan1 patches and the tablet preparation Temgesic1. These
buprenorphine products also possess abuse potential and are likely
subject to some degree of diversion, although, because of their
relatively low sales numbers, it seems unlikely that they could be a
major source of the buprenorphine that is abused. In a recent
Fig. 1. Median age of deceased in each user group during 2010–2014.
Fig.2. Age and gender distribution of deceased in each user group.
Table 3
Number of fatal buprenorphine poisonings and other causes of death in each user group. Percentages within each group are given in brackets.
Cause of death Parenteral BNX Parenteral BPN Other BNX or BPN Total
Fatal poisoning
Buprenorphine implicated 48 (68.6%) 98 (64.0%) 250 (45.3%) 396 (51.1%)
Buprenorphine primary 41 (58.6%) 78 (51.0%) 137 (24.8%) 256 (33.0%)
Other cause of death 22 (31.4%) 55 (35.9%) 302 (54.7%) 379 (48.9%)
Total 70 153 552 775
Table 4
Yearly numbers of fatal poisonings, and mortality rates in the general population of
all Finnish inhabitants aged between 15 and 64.
Fatal poisonings
Buprenorphine implicated 2010 2011 2012 2013 2014
Parenteral BNX 18 11 8 6 5
Parenteral BPN 21 25 15 18 19
Other BNX or BPN 56 60 48 45 41
All buprenorphine poisonings 95 96 71 69 65
Mortality rate (per 100,000) 2.7 2.7 2.0 2.0 1.9
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opioids was signiﬁcantly more common than injecting one’s own
OMT medication [32]. Overall, our results, along with information
from treatment programs and police sources, suggest that themajor source of abused buprenorphine in Finland is unlikely to be
diversion from OMT programs or other medical uses and is
probably trafﬁcking from abroad.
Buprenorphine was considered to be the primary ﬁnding in 256
fatal poisonings but only a few of these were mono-intoxications
by buprenorphine. In the groups which include only parenteral
users of BPN or BNX, the proportion of fatal poisonings was higher
(65.5%) than in all studied cases (51.1%) which underlines the
hazards of self-injecting buprenorphine without medical supervi-
sion.
The proportion of fatal buprenorphine poisonings was similar
in the parenteral BNX group and the parenteral BPN group. This is
an interesting ﬁnding since it suggests that the presence of the
opioid antidote naloxone in the product did not protect abusers
from fatal buprenorphine poisoning, even though naloxone alone
is regularly used to reverse opioid poisoning and intravenous BNX
Fig. 3. Manner of death in each user group.
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[33]. Our previous study, in which the data set used was
considerably smaller, found a signiﬁcantly higher proportion of
fatal buprenorphine poisonings in the parenteral BNX group
compared to parenteral BPN. Although the current, larger data set
did not conﬁrm this ﬁnding the two studies are consistent in that
neither shows evidence of a protective effect of naloxone. One
reason for the lack of evidence on the protective effect may be the
relatively short elimination half-life of naloxone (30–80 min) when
compared to that of buprenorphine (2–4 h) [34]. This may lead to
the protective effect being too short for the victim to survive.
The pharmacology of buprenorphine is complicated and not
fully evaluated which makes understanding its abuse potential and
toxicity difﬁcult. In addition, its major active metabolite, norbu-
prenorphine, has a different pharmacological proﬁle from bupre-
norphine. Norbuprenorphine is a potent, high afﬁnity agonist at m,
d, and k opioid receptors [35] whereas buprenorphine is a partial
agonist at the m-opioid receptor with antagonist activity at the
k-opioid receptor. As concentrations and concentration ratios of
buprenorphine and norbuprenorphine change over time due to
metabolism and elimination there will be a changing pattern of
pharmacological actions and interactions. Assigning toxicity to
parent compound, metabolite or to relative concentrations is not
possible with the data currently available. However, there is
evidence that norbuprenorphine causes stronger respiratory
depression than buprenorphine [15] and may contribute to the
fatal outcome in poisoning cases
Studying the few fatal poisonings in our material in which there
were no toxicological ﬁndings besides buprenorphine failed to
reveal any novel patterns or risk factors for fatal poisoning. Based
on background information, most of the victims of buprenorphine
poisoning in our study had been abusing drugs for a long time.
What caused them to die on that particular day, despite likely
having developed some degree of opioid tolerance was unclear.
Unfortunately, the background information in the forensicdatabase is far from comprehensive and does not provide sufﬁcient
detail of the circumstances of these deaths to enable identiﬁcation
of important contributory factors.
Another complicating factor is that, the respiratory depression
that can occur following the intake of buprenorphine, and in worst
cases leads to death, can be a delayed process. As a result,
buprenorphine levels at the time of death may have fallen below
the laboratory cut-offs of some forensic laboratories [10].
In a recent Swedish study it was shown that the percentage of
accidental drug poisonings was higher for those users positive for
multiple psychoactive drugs in post-mortem toxicology compared
to users positive for a single psychoactive drug [36]. Our results are
well in line with this study in that the manner of death in the
majority of the buprenorphine-positive cases was accident (60.0%
of all buprenorphine-positive cases, 61.8% of parenteral users), and
most of the fatal poisonings were poly-drug poisonings (93.9%).
Poly-drug use is a common phenomenon in many countries [1,37].
Poly-drug use and the high prevalence of buprenorphine use
among users of illegal drugs can create life-threatening inter-
actions. Although some reports point out death cases in which
nothing else was detected except buprenorphine [37] in most
studies it has been shown that buprenorphine, when used alone,
does not pose a great risk of intoxication but concomitant intake of
other central nervous system depressants can induce severe
respiratory depression and death [11].
Although parenteral use was common in our study material, the
majority of the cases did not fulﬁl the urinary concentration
criteria that would have clearly identiﬁed recent parenteral
administration. An important limitation of the study is that the
group “Other BNX and BPN”, in addition to containing all those
cases within the study material in which BNX and BPN had been
administered sublingually as prescribed, is likely to include a
number of parenteral users of both BPN and BNX. With the data
available it was not possible to determine the relative proportions
of sublingual vs. parenteral users in this group which may have
P. Kriikku et al. / Forensic Science International 291 (2018) 76–82 81affected the conclusions drawn from this material. In addition, the
method used in this study to distinguish parenteral use of
buprenorphine from sublingual use is only feasible in populations
in which BNX is the sole or primary preparation used in OMT since
medicinal use of BPN would further complicate the assessment.
The proportions of cases in each of the three groups were
similar to those in our earlier study [27] and no signiﬁcant changes
in the number of cases in each subgroup or in the total number of
cases were observed over the 5-year study period indicating that
the route of administration and the relative frequency with which
the different products were abused had not changed over that time
period.
Individuals in the parenteral groups were in general younger
than the others. Part of this difference may be explained by the
group “other BNX or BPN” including elderly individuals taking
prescribed buprenorphine preparations for the treatment of pain.
It has been shown that with increasing age, prescribed use of
opioid analgesics increases whereas non-prescribed use decreases
[38]. The majority of the studied cases (64%) were aged between 20
and 40 years and in this age group the percentage of parenteral
users was much higher than in other age groups. In all three of the
groups deﬁned by urine drug levels, the age of the deceased
increased over the ﬁve years of the study. This is in line with
previous studies on fatal poisonings of drugs addicts in general
where a similar trend has been observed [1]. A number of factors
are likely to have contributed to this trend, including national
efforts to treat those who abuse drugs. Treatment measures,
including OMT, have certainly saved lives.
There has been very little heroin use in Finland in the past 10
years and opioid abuse in this country consists almost exclusively
of buprenorphine use [1,39]. In Finland, buprenorphine has been
one of the most important causes of fatal poisonings since the year
2000 — about half of the overall drug poisoning mortality (4.61 per
100,000 inhabitants aged between 15 and 64 in 2012) [1] is
composed of buprenorphine poisoning. However, since the
number of problem opioid users in Finland in 2012 was estimated
to be about 13,800 whereas the number of patients in OMT in 2014
was 3000 [6], the majority of the users of buprenorphine are likely
to be outside of OMT programs. Thus, despite the fatalities
associated with abuse of buprenorphine, our results cannot be
used to evaluate the safety of buprenorphine in OMT. In fact,
previous studies have shown buprenorphine to be safer in OMT
compared to methadone [40,41].
Overall, the number of fatal drug poisonings has decreased in
Finland in recent years. The same phenomenon has been seen in
alcohol poisonings. In this study, the number of fatal buprenor-
phine poisonings decreased in the study period. The number of
fatal poisonings would probably be higher if problem opioid users
injected heroin instead of buprenorphine [42].
5. Conclusion
We conclude that parenteral use of buprenorphine-containing
products is an ongoing and relatively prevalent phenomenon in
Finland. In at least 28.8% of the buprenorphine-positive cases in the
study period the drug had been administered parenterally,
indicating abuse rather than medical use. The majority of the
identiﬁed parenteral users had used BPN. Despite the presence of
naloxone in BNX, this product is also abused and the percentage of
parenteral BNX users in which the pathologist implicated
buprenorphine in the cause of death was similar to that for
parenteral BPN users. In most of the studied cases the deceased had
used other drugs and/or alcohol along with buprenorphine which
likely had contributed to the fatal outcome. The number of cases
per year remained relatively constant over the study period but the
mean age of the deceased increased signiﬁcantly.Author contribution statement
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